Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$26.98 USD
-0.56 (-2.03%)
Updated May 20, 2024 04:00 PM ET
After-Market: $26.96 -0.02 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.98 USD
-0.56 (-2.03%)
Updated May 20, 2024 04:00 PM ET
After-Market: $26.96 -0.02 (-0.07%) 7:58 PM ET
5-Strong Sell of 5 5
B Value D Growth D Momentum C VGM
Zacks News
Integra (IART) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair
by Zacks Equity Research
Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.
Is Integra LifeSciences (IART) a Worthy Value Investor Pick?
by Zacks Equity Research
Let's see if Integra LifeSciences (IART) stock is a good choice for value-oriented investors right now from multiple angles.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and robust segmental performance.
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops
by Zacks Equity Research
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.
Integra LifeSciences (IART) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.20% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Announces Preliminary Q4 & '21 Sales Results
by Zacks Equity Research
Integra's (IART) preliminary revenue results and recent plans to implement a $125-million share repurchase instill investor optimism.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) strong third-quarter performance and ongoing recovery across its business.
Integra (IART) Businesses Rebound Despite Supply Issues
by Zacks Equity Research
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Integra (IART) Down 13.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.
Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.
Integra LifeSciences (IART) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 19.44% and 0.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Integra LifeSciences (IART) Q3 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Integra LifeSciences (IART) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 17.91% and 3.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Integra LifeSciences (IART) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra (IART) Releases Favorable PriMatrix Clinical Outcome
by Zacks Equity Research
Integra's (IART) PriMatrix study data validates that one application of PriMatrix is needed to address hard-to-heal diabetic foot ulcers.
Integra's (IART) SurgiMend Gets Innovative Technology Contract
by Zacks Equity Research
Integra's (IART) SurgiMend Collagen Matrix is recognized as a product that can potentially bring improvement to the health care industry.
Integra (IART) Tissue Technologies Rebounds Amid Supply Woe
by Zacks Equity Research
Integra's (IART) CSS segment too reflects a gradual recovery in procedure-based market as well as an improvement in hospital capital spending during the first quarter.
Integra (IART) Down 8.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.